 |
Naltrexone HCl |
|---|---|
| Trade Name | Trexan |
| Orphan Indication | For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals |
| USA Market Approval | USA |
| USA Designation Date | 1985-03-11 00:00:00 |
| Sponsor | DuPont Pharmaceuticals;E.I. Du Pont De Nemours & Co.;Wilmington, Delaware, 19898 |
